Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Prime Medicine, Inc. (PRME) announced on Thursday the appointment of Svetlana Makhni as the company's new Chief Financial Officer. The company, which focuses on the development of a new class of differentiated, one-time curative genetic therapies, seeks to strengthen its financial leadership as it advances its therapeutic pipeline. Makhni joins Prime Medicine with a deep background in the biotech and pharmaceutical sectors. She most recently served as the CFO of Marengo Therapeutics, a clinical-stage company specializing in immuno-oncology. Her expertise in managing the financial complexities of clinical-stage ventures is expected to be an asset to the firm. In addition to her time at Marengo, Makhni's professional history includes serving as the CFO of Escient Pharmaceuticals. She also previously held the dual role of CFO and Head of Operations at Bierman ABA, demonstrating a broad range of operational and financial management experience. While executive transitions are common in the biotech industry, the appointment of a seasoned financial officer is a key step for companies in the development phase. This move ensures that Prime Medicine maintains rigorous fiscal oversight as it navigates the costly and complex process of bringing genetic therapies to market.